European Biotechnology Magazine Winter 2024
Berlin, 5 December 2024 – Monoclonal antibodies have been the cornerstone of precision medicine and continue to dominate the $417 billion biologicals market. However, after decades of development, new treatment options are now entering the market. These include advanced versions of artificial bispecific antibodies, antibody-drug conjugates, and other engineered proteins used in immune receptor-based therapies such as CAR-T and TCR-T cell therapies. European Biotechnology Magazine takes a detailed look at the topics discussed at the PEGS Europe Summit in Barcelona.
In this issue:
- Cover story and thematic focus: New proteins on the market
- Country alliance calls for the establishment of a European protein strategy
- Climate paralysis at COP29 in Baku
- EU Commission invites industry feedback on the Novo/Catalent deal
- Interview: Thomas Lingelbach, CEO, Valneva SE
- 30 years of BIO-Europe – Focus on Scandinavia
- IP – Unified Patent System. Quo vadis?
- Interview: Nina Kreymborg, SVP/CSO Partner Team at Curie.bio
- Italy: Pension funds required to invest in start-ups
- Current clinical trials, stock market updates
- News from Europe, updates from BIOTECH Austria, the Society for Laboratory Automation and Screening (SLAS), and the Young European Biotech Network
- SPECIAL: Protein Engineering & Services
Read the latest issue here.